Literature DB >> 2197073

Management strategies for weight control. Eating, exercise and behaviour.

I D Caterson1.   

Abstract

Obesity is a major health and social problem worldwide for which no single satisfactory treatment exists. Because of the prevalence of the disease, numerous therapeutic strategies have been attempted--often unsuccessfully. Weight loss programmes based on dietary restriction of caloric intake and nutritional education, exercise, surgical (gastroplasty, gastric bypass) and procedural (gastric balloon, waist cord, jaw wiring, liposuction) intervention and pharmacotherapy (appetite suppressants, thermogenic agents, bulking agents) used alone or in combination, have produced weight loss in the short to medium term; however, weight is generally regained on discontinuation of treatment. Behaviour modification programmes appear to offer the highest success rate in the long term. Weight loss is not rapid, although losses of 10 to 15 kg have been achieved after 6 months, and this may be increased when behaviour modification therapy is combined with more aggressive treatments such as severe caloric restriction or jaw wiring. Behaviour modification is particularly beneficial in special patient groups such as the obese elderly, children or adolescents, and disabled patients. Thus, although it appears that each of the treatments developed for the management of obese patients has its place, the cornerstone of therapy for most patients remains a programme of dietary restriction, combined with exercise and behaviour modification.

Entities:  

Mesh:

Year:  1990        PMID: 2197073     DOI: 10.2165/00003495-199000393-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  96 in total

1.  Gastric balloons to treat obesity. How safe? How effective?

Authors:  J W Hamilton
Journal:  Postgrad Med       Date:  1988-05-01       Impact factor: 3.840

2.  Gastric banding for morbid obesity: early results.

Authors:  T Løvig; J F Haffner; K Nygaard; J O Stadaas
Journal:  Int J Obes       Date:  1987

3.  Cirrhosis and death after jejunoileal shunt.

Authors:  D B McGill; S R Humpherys; A H Baggenstoss; E R Dickson
Journal:  Gastroenterology       Date:  1972-11       Impact factor: 22.682

4.  Surgical treatment of obesity.

Authors:  J H Payne; L T DeWind
Journal:  Am J Surg       Date:  1969-08       Impact factor: 2.565

5.  Behavior modification for obesity: the evaluation of exercise, contingency management, and program adherence.

Authors:  P M Stalonas; W G Johnson; M Christ
Journal:  J Consult Clin Psychol       Date:  1978-06

6.  Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares.

Authors:  C E Sullivan; F G Issa; M Berthon-Jones; L Eves
Journal:  Lancet       Date:  1981-04-18       Impact factor: 79.321

7.  Obesity and psychoanalysis.

Authors:  C Rand; A J Stunkard
Journal:  Am J Psychiatry       Date:  1978-05       Impact factor: 18.112

8.  Changes in plasma lipid and lipoprotein levels in men and women after a program of moderate exercise.

Authors:  K D Brownell; P S Bachorik; R S Ayerle
Journal:  Circulation       Date:  1982-03       Impact factor: 29.690

Review 9.  Outpatient treatments of obesity: a comparison of methodology and clinical results.

Authors:  R R Wing; R W Jeffery
Journal:  Int J Obes       Date:  1979

10.  The effectiveness of gastric bypass over gastric partition in morbid obesity: consequence of distal gastric and duodenal exclusion.

Authors:  W J Pories; E G Flickinger; D Meelheim; A M Van Rij; F T Thomas
Journal:  Ann Surg       Date:  1982-10       Impact factor: 12.969

View more
  2 in total

Review 1.  Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.

Authors:  R Davis; D Faulds
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 2.  Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity.

Authors:  D McTavish; R C Heel
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.